The present study has assessed the role of the LXR agonist DMHCA in reducing tumorigenesis and ameliorating fibrosis and immune tolerance in the NeuT/ATTAC fibrosis model of ErbB2 neoplasia [27]. Here, ERBB2 is linked to neoplasm.